Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199179 | 0.97 | HPGD (0.50) | HPGDSLC29A1HDAC1HDAC6ADORA2A | |
| SCHEMBL29208373 | 0.95 | HPGD (0.48) | HPGDSLC29A1HDAC1HDAC6ADORA2A | |
| SCHEMBL29208349 | 0.92 | HPGD (0.48) | HPGDSLC29A1HDAC1HDAC6ADORA2A | |
| SCHEMBL1312875 | 0.90 | HPGD (0.48) | HPGDSLC29A1HDAC1HDAC6ADORA2A | |
| SCHEMBL12112160 | 0.89 | PDE10A (0.48) | SLC29A1HDAC6ADORA2AFGFR1FGFR4 | |
| SCHEMBL12112213 | 0.88 | PDE10A (0.42) | HPGDSLC29A1HDAC1HDAC6ADORA2A | |
| SCHEMBL16123784 | 0.86 | SLC29A1 (0.46) | SLC29A1HDAC6ADORA2AFGFR1FGFR4 | |
| SCHEMBL13394148 | 0.85 | SLC29A1 (0.47) | SLC29A1HDAC6ADORA2AFGFR1FGFR4 | |
| SCHEMBL15214749 | 0.85 | ADORA2A (0.47) | SLC29A1HDAC6ADORA2AFGFR1FGFR4 | |
| SCHEMBL15214751 | 0.85 | PDE10A (0.51) | SLC29A1HDAC1HDAC6ADORA2AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115201-A1 | POTENTIAL THERAPEUTICS FOR FIBROSIS BY BLOCKING THE INCREASE OF A KEY ENZYME | TEXAS A & M UNIV SYS (US) | 2026-04-30 | — | — | US | claimed |
| US-12569499-B2 | Intravenous formulations of RK-33 | NATSAR PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4395765-A1 | INTRAVENOUS FORMULATIONS OF RK-33 | Natsar Pharmaceuticals, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| US-11976073-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2024-05-07 | — | — | US | claimed |
| US-20240138263-A1 | LIGHT EMITTING ELEMENT AND POLYCYCLIC COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-04-25 | — | — | US | claimed |
| WO-2024081018-A1 | POTENTIAL THERAPEUTICS FOR FIBROSIS BY BLOCKING THE INCREASE OF A KEY ENZYME | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-04-18 | — | — | WO | claimed |
| CN-116769915-A | Marker detection object for breast cancer diagnosis or prognosis evaluation, application thereof, kit and targeted inhibitor | 中国医科大学附属第一医院 | 2023-09-19 | — | — | CN | claimed |
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | claimed |
| US-20230183250-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-15 | — | — | US | claimed |
| US-20230077636-A1 | INTRAVENOUS FORMULATIONS OF RK-33 | NATSAR PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | claimed |
| WO-2023034743-A1 | INTRAVENOUS FORMULATIONS OF RK-33 | NATSAR PHARMACEUTICALS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-20260115201-A1 | POTENTIAL THERAPEUTICS FOR FIBROSIS BY BLOCKING THE INCREASE OF A KEY ENZYME | TEXAS A & M UNIV SYS (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2012122471-A2 | COMPOUNDS AND METHODS OF USE IN ABLATIVE RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | HOSMANE, RAMACHANDRA S. | 2011-11-10 | — | — | US | disclosed |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | HOSMANE, RAMACHANDRA S. | 2011-11-10 | — | — | US | disclosed |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | HOSMANE, RAMACHANDRA S. | 2011-11-10 | — | — | US | disclosed |
| WO-2010039187-A2 | FUSED DIIMIDAZODIAZEPINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569499-B2 | Intravenous formulations of RK-33 | DDX3X, DDX39B, HNRNPA3 | HPGD 4163/4885SLC29A1 1283/4885HDAC1 1194/4885 |
| US-20230183250-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | HPGD 980/4885SLC29A1 1255/4885HDAC1 148/4885 |
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | HPGD 980/4885SLC29A1 1255/4885HDAC1 148/4885 |
| US-11976073-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CCNI, CDK1 | HPGD 980/4885SLC29A1 1255/4885HDAC1 148/4885 |
| US-20260115201-A1 | POTENTIAL THERAPEUTICS FOR FIBROSIS BY BLOCKING THE INCREASE OF A KEY ENZYME | DDX3X, DDX39B, DDX1 | HPGD 4065/4885SLC29A1 1577/4885HDAC1 2129/4885 |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | GLRB, SRR, HCAR3 | HPGD 1791/4885SLC29A1 1542/4885HDAC1 1317/4885 |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | IKZF3, AADAC, IKBKE | HPGD 750/4885SLC29A1 3265/4885HDAC1 51/4885 |
| US-20230077636-A1 | INTRAVENOUS FORMULATIONS OF RK-33 | IL33, TRIM33, PRKD3 | HPGD 2915/4885SLC29A1 935/4885HDAC1 3785/4885 |
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | IL15, IL15RA, CD4 | HPGD 2395/4885SLC29A1 2287/4885HDAC1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.